Merit Medical Launches the Resilience Through-the-Scope Esophageal Stent

Rhea-AI Summary

Merit Medical (NASDAQ: MMSI) announced the US commercial launch of the Resilience Through-the-Scope (TTS) Esophageal Stent on March 16, 2026. The stent is indicated for esophageal fistulas and malignant strictures and features proprietary anti-migration flanges, a single-handed deployment system, and unique sizes 14x50, 17x50, and 20x50 mm to address placement and migration challenges.

Positive

• US commercial release on March 16, 2026
• Unique market sizes: 14×50, 17×50, 20×50 mm
• Proprietary anti-migration flanges claiming highest migration resistance
• Single-handed deployment system for improved placement control

Negative

• Migration resistance claim supported by bench data (not clinical outcomes)
• Indication limited to esophageal fistulas and malignant strictures, not broader esophageal uses

News Market Reaction – MMSI

-1.12%

-1.12% Session close to close

In the Mar 16 session, MMSI declined 1.12%, reflecting a mild negative market reaction.

Data tracked by StockTitan Argus on the day of publication.

Market Context

This announcement highlights Merit’s continued build‑out of its endoscopy offering with the Resilien...

Analysis

This announcement highlights Merit’s continued build‑out of its endoscopy offering with the Resilience TTS esophageal stent, targeting fistulas and malignant strictures with anti‑migration features and unique 14–20 mm x 50 mm sizes. It follows recent periods of solid revenue growth, new guidance, and prior product and clinical milestones. Investors may watch how this device contributes to procedure volumes, supports the oncology and endoscopy franchises, and fits within broader commercialization and reimbursement trends.

Key Figures

Stent size option: 14 mm x 50 mm Stent size option: 17 mm x 50 mm Stent size option: 20 mm x 50 mm +4 more

7 metrics

Stent size option 14 mm x 50 mm Resilience TTS esophageal stent size

Stent size option 17 mm x 50 mm Resilience TTS esophageal stent size

Stent size option 20 mm x 50 mm Resilience TTS esophageal stent size

Company founded 1987 Year Merit Medical was founded

Sales & clinical staff more than 800 individuals Domestic and international sales force and clinical support team

Employees approximately 7,600 people Total employees worldwide

Cancer rank sixth most common cause Esophageal cancer as cause of cancer deaths worldwide

Historical Context

5 past events · Latest: Feb 24 (Positive)

Pattern 5 events

Date	Event	Sentiment	24h Move	Catalyst
Feb 24	Earnings & guidance	Positive	-3.9%	Reported strong 2025 growth and raised 2026 guidance with higher EPS outlook.
Jan 08	Board & prelim results	Positive	-7.3%	Announced new board chair and double‑digit Q4 revenue growth in preliminary results.
Dec 23	Conference participation	Neutral	-0.3%	Planned presentation at the J.P. Morgan Healthcare Conference with company overview.
Nov 13	Reimbursement update	Negative	-2.6%	CMS deferred WRAPSODY TPT decision; company pivoted to immediate full U.S. commercialization.
Nov 05	Clinical trial results	Positive	-1.5%	Released WAVE trial 24‑month data showing WRAPSODY CIE superiority versus PTA.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Pattern Detected

Recent history shows several instances where positive operational or financial updates were followed by negative price reactions, indicating a tendency for the stock to sell off on good news.

Recent Company History

Over the past six months, Merit Medical reported strong Q4 2025 and full-year results with $1.516B revenue and higher 2026 guidance, yet shares fell after earnings-related releases. The company highlighted WRAPSODY® commercialization and positive 24‑month WAVE trial data, but those updates also coincided with modest declines. Earlier, board leadership changes and a J.P. Morgan conference appearance had limited or negative impact. Today’s esophageal stent launch continues a pattern of product and portfolio expansion within endoscopy on top of this growth backdrop.

Key Terms

through-the-scope, esophageal stent, esophageal fistulas, malignant strictures

4 terms

through-the-scope medical

"announced the US commercial release of the Resilience Through-the-Scope (TTS) Esophageal Stent"

Through-the-scope describes medical devices or procedures performed by passing tools through the working channel of an endoscope — a flexible tube with a camera used to view inside the body — so instruments can be delivered while the doctor watches on screen. For investors, it signals a product design and clinical workflow choice that can shorten procedure time, reduce equipment swaps and influence adoption, pricing and reimbursement in the market, much like a camera with a built-in accessory port that speeds setup and use.

esophageal stent medical

"announced the US commercial release of the Resilience Through-the-Scope (TTS) Esophageal Stent"

An esophageal stent is a small tube, often made of metal or plastic, that doctors place inside the esophagus to prop it open when it is narrowed by disease or damaged after surgery. Think of it like a tiny scaffold that keeps a clogged or leaky pipe working so food and fluids can pass. Investors care because sales, reimbursement rules, safety data and regulatory approvals for these devices directly affect revenue and risks for medical-device and healthcare companies.

esophageal fistulas medical

"indicated for treatment of esophageal fistulas and strictures (narrowing) caused by malignant tumors"

An esophageal fistula is an abnormal opening that creates a leak between the swallowing tube (esophagus) and another nearby structure, allowing food, saliva or air to escape where it shouldn’t—like a plumbing breach between two pipes. For investors, it matters because such a complication signals serious safety risks that can halt or delay clinical trials, trigger regulatory actions, increase treatment costs and liability, and reduce market acceptance of related drugs or devices.

malignant strictures medical

"esophageal fistulas and strictures (narrowing) caused by malignant tumors"

Malignant strictures are narrowings of a body passage caused by cancerous growths—think of a clogged pipe where a tumor squeezes or blocks a tube such as the esophagus, bile duct or airway. For investors, they signal clinical need for drugs, procedures, stents and diagnostic tools, influence clinical trial design and potential market size, and can affect reimbursement and regulatory pathways for companies developing treatments or devices.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

New Resilience™ deployment system, anti-migration stent design, and unique stent sizes offer physicians control while enhancing treatment for patients with esophageal fistulas and malignant strictures

SOUTH JORDAN, Utah, March 16, 2026 (GLOBE NEWSWIRE) -- Merit Medical Systems, Inc. (NASDAQ: MMSI), a global leader of healthcare technology, today announced the US commercial release of the Resilience Through-the-Scope (TTS) Esophageal Stent.

The Resilience stent is the newest product in Merit’s Endoscopy portfolio, joining a comprehensive offering of treatment options for patients with disease in the esophagus. The new stent is indicated for treatment of esophageal fistulas and strictures (narrowing) caused by malignant tumors.

Esophageal cancer is the sixth most common cause of cancer deaths worldwide.¹ Symptoms of esophageal cancer include trouble swallowing, regurgitation, and chest pain. These gradually worsen over time, with an increase in pain when swallowing as the esophagus narrows from the growing cancer.

To care for this patient population, the Resilience stent was developed with proprietary anti-migration flanges to anchor the stent in place.^2,3 In addition, it is designed to demonstrate the greatest migration resistance among currently available TTS stents.

A single-handed deployment system provides clinicians with control for easy and accurate placement.² To meet a variety of clinical needs, Resilience is the only stent on the market offered in sizes 14 mm x 50 mm, 17 mm x 50 mm, and 20 mm x 50 mm.²

Learn more about Resilience.

“The Resilience TTS Esophageal Stent fulfills an unmet need with its unique sizes, design, easy-to-use delivery system, and anti-migration properties,” said Stuart K Amateau, MD, PhD, Professor and Chief Division of Gastroenterology, Hepatology, and Nutrition at the University of Minnesota Medical Center in Minneapolis, MN.

The Resilience stent addresses several well-known clinical disadvantages of currently available TTS esophageal stents,” said Martha G. Aronson, Merit’s President and Chief Executive Officer. “This launch signifies another step forward in the rapidly growing TTS stent-technology market. At Merit, we continually strive to understand clinical needs and deliver innovation that advances the care patients receive.”

^{1. Huang et al. 2021. “Global Burden, Risk Factors, and Trends of Esophageal Cancer: An Analysis of Cancer Registries from 48 Countries.” Cancers (Basel) 13, no. 1 (Jan): 141. doi: 10.3390/cancers13010141.}

^{2. Bench Data on File.}

^{3. Mozafari et al. 2018. “Migration Resistance of Esophageal Stents: The Role of Stent Design.” Comput Biol Med 100 (Sept): 43–49. doi: 10.1016/j.compbiomed.2018.06.031.}

ABOUT MERIT MEDICAL
Founded in 1987, Merit Medical Systems, Inc. is engaged in the development, manufacture, and distribution of proprietary medical devices used in interventional, diagnostic, and therapeutic procedures, particularly in cardiology, radiology, oncology, critical care, and endoscopy. Merit serves customers worldwide with a domestic and international sales force and clinical support team totaling more than 800 individuals. Merit employs approximately 7,600 people worldwide.

CONTACTS

PR/Media Inquiries 
Sarah Comstock
Merit Medical 
+1-801-432-2864 | sarah.comstock@merit.com 

Investor Inquiries 
Mike Piccinino, CFA, IRC 
ICR Healthcare
+1-443-213-0509 | mike.piccinino@icrhealthcare.com

FAQ

What is the Resilience TTS Esophageal Stent released by Merit Medical (MMSI) on March 16, 2026?

It is a US commercial esophageal stent for fistulas and malignant strictures, launched March 16, 2026. According to Merit Medical, it features anti-migration flanges, a single-handed deployment system, and unique sizes 14×50, 17×50, and 20×50 mm to aid placement.

What sizes does the Merit Resilience esophageal stent (MMSI) come in and why does that matter?

Resilience is offered in 14×50, 17×50, and 20×50 mm sizes to address varied anatomy. According to Merit Medical, these unique sizes aim to meet diverse clinical needs and provide options not previously available among TTS stents.

How does the Resilience stent (MMSI) claim to reduce stent migration?

The stent uses proprietary anti-migration flanges designed to anchor the device and resist movement. According to Merit Medical, bench data indicate the Resilience design demonstrates the greatest migration resistance among currently available TTS stents.

What deployment features does the Resilience TTS stent (MMSI) offer clinicians?

It offers a single-handed deployment system intended for easy, accurate placement during procedures. According to Merit Medical, this design gives clinicians enhanced control for more precise stent positioning in the esophagus.

For which conditions is the Resilience esophageal stent (MMSI) indicated?

The stent is indicated for esophageal fistulas and strictures caused by malignant tumors. According to Merit Medical, these indications target symptomatic narrowing and leaks associated with esophageal cancer.

Does Merit Medical (MMSI) provide clinical outcome data for the Resilience TTS stent yet?

The announcement cites bench data and literature but does not provide clinical outcome results in this release. According to Merit Medical, migration resistance is supported by bench testing rather than published clinical trial outcomes.